Literature DB >> 19617321

Initial evaluation of 11C-DPA-713, a novel TSPO PET ligand, in humans.

Christopher J Endres1, Martin G Pomper, Michelle James, Ovsev Uzuner, Dima A Hammoud, Crystal C Watkins, Aaron Reynolds, John Hilton, Robert F Dannals, Michael Kassiou.   

Abstract

UNLABELLED: Translocator protein (TSPO) is upregulated in activated microglia and thus can serve as a marker of neuroinflammation. Recently, a novel radioligand, (11)C-N,N-diethyl-2-[2-(4-methoxyphenyl)-5,7-dimethyl-pyrazolo[1,5-a]pyrimidin-3-yl]-acetamide ((11)C-DPA-713), has been described that binds to TSPO with high affinity. Here, we report the first examination of (11)C-DPA-713 in human subjects using PET.
METHODS: Five healthy controls were studied with PET for 90 min after a bolus injection of high-specific-activity (11)C-DPA-713. For comparison, 2 additional healthy controls were studied with (11)C-R-PK11195. Arterial blood sampling and metabolite analysis were performed to allow the accurate quantification of tracer kinetics. Tracer uptake was evaluated for several brain regions. Tissue time-activity curves were fitted using 1- and 2-tissue-compartment models, with goodness-of-fit tests showing a preference for the 2-tissue model.
RESULTS: In the healthy brain, the average plasma-to-tissue clearance and the total volume of distribution were an order of magnitude larger than measured for (11)C-R-PK11195. Accordingly, dose-normalized time-activity curves showed that (11)C-DPA-713 gives a larger brain signal.
CONCLUSION: Studies in patient populations will help determine whether (11)C-DPA-713 provides better sensitivity for evaluating increased TSPO expression. This initial study in humans shows that (11)C-DPA-713 is a promising ligand for evaluating TSPO binding with PET.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19617321      PMCID: PMC2883612          DOI: 10.2967/jnumed.109.062265

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  30 in total

1.  Column-switching HPLC for the analysis of plasma in PET imaging studies.

Authors:  J Hilton; F Yokoi; R F Dannals; H T Ravert; Z Szabo; D F Wong
Journal:  Nucl Med Biol       Date:  2000-08       Impact factor: 2.408

2.  Compartmental analysis of [11C]flumazenil kinetics for the estimation of ligand transport rate and receptor distribution using positron emission tomography.

Authors:  R A Koeppe; V A Holthoff; K A Frey; M R Kilbourn; D E Kuhl
Journal:  J Cereb Blood Flow Metab       Date:  1991-09       Impact factor: 6.200

Review 3.  Microglia: a sensor for pathological events in the CNS.

Authors:  G W Kreutzberg
Journal:  Trends Neurosci       Date:  1996-08       Impact factor: 13.837

4.  PK ('peripheral benzodiazepine')--binding sites in the CNS indicate early and discrete brain lesions: microautoradiographic detection of [3H]PK11195 binding to activated microglia.

Authors:  R B Banati; R Myers; G W Kreutzberg
Journal:  J Neurocytol       Date:  1997-02

5.  Quantification of brain mu-opioid receptors with [11C]carfentanil: reference-tissue methods.

Authors:  Christopher J Endres; Badreddine Bencherif; John Hilton; Igal Madar; J James Frost
Journal:  Nucl Med Biol       Date:  2003-02       Impact factor: 2.408

6.  Kinetic modeling of N-[11C]methylpiperidin-4-yl propionate: alternatives for analysis of an irreversible positron emission tomography trace for measurement of acetylcholinesterase activity in human brain.

Authors:  R A Koeppe; K A Frey; S E Snyder; P Meyer; M R Kilbourn; D E Kuhl
Journal:  J Cereb Blood Flow Metab       Date:  1999-10       Impact factor: 6.200

7.  2-Arylpyrazolo[1,5-a]pyrimidin-3-yl acetamides. New potent and selective peripheral benzodiazepine receptor ligands.

Authors:  S Selleri; F Bruni; C Costagli; A Costanzo; G Guerrini; G Ciciani; B Costa; C Martini
Journal:  Bioorg Med Chem       Date:  2001-10       Impact factor: 3.641

8.  Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects.

Authors:  J Logan; J S Fowler; N D Volkow; A P Wolf; S L Dewey; D J Schlyer; R R MacGregor; R Hitzemann; B Bendriem; S J Gatley
Journal:  J Cereb Blood Flow Metab       Date:  1990-09       Impact factor: 6.200

9.  Expression of the translocator protein of 18 kDa by microglia, macrophages and astrocytes based on immunohistochemical localization in abnormal human brain.

Authors:  M Cosenza-Nashat; M-L Zhao; H-S Suh; J Morgan; R Natividad; S Morgello; S C Lee
Journal:  Neuropathol Appl Neurobiol       Date:  2008-12-11       Impact factor: 8.090

10.  Novel peripheral benzodiazepine receptor ligand [11C]DAA1106 for PET: an imaging tool for glial cells in the brain.

Authors:  Jun Maeda; Tetsuya Suhara; Ming-Rong Zhang; Takashi Okauchi; Fumihiko Yasuno; Yoko Ikoma; Motoki Inaji; Yuji Nagai; Akihiro Takano; Shigeru Obayashi; Kazutoshi Suzuki
Journal:  Synapse       Date:  2004-06-15       Impact factor: 2.562

View more
  65 in total

1.  Decreased microglial activation in MS patients treated with glatiramer acetate.

Authors:  John N Ratchford; Christopher J Endres; Dima A Hammoud; Martin G Pomper; Navid Shiee; John McGready; Dzung L Pham; Peter A Calabresi
Journal:  J Neurol       Date:  2011-12-09       Impact factor: 4.849

Review 2.  Plasma radiometabolite correction in dynamic PET studies: Insights on the available modeling approaches.

Authors:  Matteo Tonietto; Gaia Rizzo; Mattia Veronese; Masahiro Fujita; Sami S Zoghbi; Paolo Zanotti-Fregonara; Alessandra Bertoldo
Journal:  J Cereb Blood Flow Metab       Date:  2015-10-14       Impact factor: 6.200

3.  Biodistribution and Radiation Dosimetry of 124I-DPA-713, a PET Radiotracer for Macrophage-Associated Inflammation.

Authors:  Catherine A Foss; Donika Plyku; Alvaro A Ordonez; Julian Sanchez-Bautista; Hailey B Rosenthal; Il Minn; Martin A Lodge; Martin G Pomper; George Sgouros; Sanjay K Jain
Journal:  J Nucl Med       Date:  2018-04-26       Impact factor: 10.057

Review 4.  Brain PET Imaging: Value for Understanding the Pathophysiology of HIV-associated Neurocognitive Disorder (HAND).

Authors:  Sanhita Sinharay; Dima A Hammoud
Journal:  Curr HIV/AIDS Rep       Date:  2019-02       Impact factor: 5.071

Review 5.  Imaging Biomarkers of the Neuroimmune System among Substance Use Disorders: A Systematic Review.

Authors:  Eric A Woodcock; Ansel T Hillmer; Graeme F Mason; Kelly P Cosgrove
Journal:  Mol Neuropsychiatry       Date:  2019-05-09

6.  Current imaging strategies in rheumatoid arthritis.

Authors:  Merissa N Zeman; Peter Jh Scott
Journal:  Am J Nucl Med Mol Imaging       Date:  2012-03-28

Review 7.  In vivo PET imaging of neuroinflammation in Alzheimer's disease.

Authors:  Julien Lagarde; Marie Sarazin; Michel Bottlaender
Journal:  J Neural Transm (Vienna)       Date:  2017-05-17       Impact factor: 3.575

8.  Translocator protein (TSPO) and stress cascades in mouse models of psychosis with inflammatory disturbances.

Authors:  Daisuke Fukudome; Lindsay N Hayes; Travis E Faust; Catherine A Foss; Mari A Kondo; Brian J Lee; Atsushi Saito; Shin-Ichi Kano; Jennifer M Coughlin; Atsushi Kamiya; Martin G Pomper; Akira Sawa; Minae Niwa
Journal:  Schizophr Res       Date:  2018-02-03       Impact factor: 4.939

9.  Isolated spinal cord contusion in rats induces chronic brain neuroinflammation, neurodegeneration, and cognitive impairment. Involvement of cell cycle activation.

Authors:  Junfang Wu; Bogdan A Stoica; Tao Luo; Boris Sabirzhanov; Zaorui Zhao; Kelsey Guanciale; Suresh K Nayar; Catherine A Foss; Martin G Pomper; Alan I Faden
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

10.  Translocator protein ligands based on N-methyl-(quinolin-4-yl)oxypropanamides with properties suitable for PET radioligand development.

Authors:  Chad Brouwer; Kimberly J Jenko; Sami S Zoghbi; Cheryl L Morse; Robert B Innis; Victor W Pike
Journal:  Eur J Med Chem       Date:  2016-08-25       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.